SpringWorks Therapeutics (NASDAQ: SWTX)
$36.13
(-0.6%)
-$0.21
Price as of December 31, 2024, 4:00 p.m. ET
SpringWorks Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
SpringWorks Therapeutics Company Info
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, BGB-3245 (RAF Fusion and Dimer Inhibitor), SW-682 (TEAD Inhibitor), and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.
News & Analysis
Featured Article
What Company Will Eli Lilly Buy Next?
Following the announced buyout of Dermira, Eli Lilly’s management said more acquisitions are in store for 2020.
David Haen | Jan 23, 2020
Featured Article
Here's Why SpringWorks Therapeutics Climbed 69% in December
The stock climbed after investors saw encouraging signs from a similar program.
Cory Renauer | Jan 12, 2020
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.